FREE Case Evaluation: 1-888-887-3117
The latest news on the roundup settlement reveals an ongoing legal and financial crisis for Bayer, with approximately 60,000 active lawsuits still pending as of January 2026, despite the company already paying out over $10 billion to settle roughly 100,000 claims since 2020. Here's what you need to know right now:
Key Updates (January 2026):
What This Means for Victims:
If you used Roundup regularly and were diagnosed with non-Hodgkin lymphoma or related cancers after June 1, 2018, you may still qualify for compensation. However, state-specific deadlines apply, and the Supreme Court's upcoming decision could dramatically reshape the litigation landscape.
The Roundup litigation represents one of the largest product liability battles in U.S. history. At its core is a simple but devastating claim: Bayer's glyphosate-based weed killer causes cancer, and the company knew about the risks but failed to warn consumers. Since the first jury verdict in 2018, thousands of individuals who developed non-Hodgkin lymphoma after years of using Roundup have filed lawsuits, leading to massive settlements and billion-dollar verdicts.
But the fight is far from over. While Bayer has settled many claims, tens of thousands remain active. The company is waging a multi-front legal war—appealing verdicts, pushing for federal preemption arguments, lobbying state legislatures, and even exploring bankruptcy for Monsanto. Meanwhile, new cases continue to be filed, and recent verdicts show juries remain willing to award staggering damages.
The stakes are enormous. For Bayer, the litigation threatens the company's financial stability and future. For victims, it represents a chance to hold a multinational corporation accountable for prioritizing profits over public safety. And for anyone who has used Roundup and is now facing a cancer diagnosis, understanding the latest news on the roundup settlement is critical to making informed decisions about legal action.
I'm Tim Burd, CEO of Justice Hero, where we help connect individuals harmed by dangerous products with experienced attorneys who can fight for their rights. Through my work, I've seen how confusing and overwhelming the legal process can be for victims, which is why I'm committed to providing clear, accurate information about the latest news on the roundup settlement and helping people understand their options.
Timeline Overview:
Explore more about the latest news on the roundup settlement:
As we dig into early 2026, the legal landscape surrounding Roundup remains incredibly dynamic. Despite years of intense litigation and billions already paid out, the fight is far from over. Bayer, the German pharmaceutical and life sciences giant that acquired Monsanto in 2018, continues to grapple with a massive number of outstanding lawsuits. This ongoing legal battle has significant implications, not just for the company and the plaintiffs, but for the broader legal and regulatory environment concerning product liability.
The sheer volume of active cases is staggering. As of January 2026, Bayer still faces around 60,000 active lawsuits alleging that Roundup caused cancer. A significant portion of these cases are consolidated in a federal multidistrict litigation (MDL) in California. Specifically, 4,511 Roundup lawsuits were pending in the federal MDL in a California federal court as of January 2026, with the total number of active federal lawsuits exceeding 4,500 by December 2025. This California-based MDL, overseen by U.S. District Judge Vince Chhabria, is a central hub for these complex cases.
The financial toll on Bayer has been immense. Since acquiring Monsanto, Bayer's stock has reportedly dropped more than 70%. The company has had to set aside substantial funds to cover its legal liabilities. As of August 2025, Bayer had established about $1.3 billion in provisions for the Roundup litigation, with 61,000 unresolved claims. This figure increased, with another $1.1 billion set aside by November 2025, bringing the total provisions to almost $1.4 billion by August 2025. These provisions underscore the anticipated costs associated with resolving the remaining cases. Bayer even lowered its expected earnings for 2025 by about $4 billion, explicitly citing costs associated with Roundup lawsuits. It’s clear that the litigation is not just a legal headache but a significant financial drain.
For more detailed information on the ongoing litigation, explore our dedicated page on Roundup litigation updates.
While the MDL in California processes many cases, individual trials continue to take place across the country, often resulting in massive jury verdicts that capture headlines and fuel the plaintiffs' resolve. Our home state of California has seen some of the earliest and largest verdicts against Monsanto. For instance, a California state jury awarded $289 million to a Roundup plaintiff in August 2018, followed by $80 million in March 2019, and a staggering $2 billion to a Roundup plaintiff couple in May 2019. More recently, in October 2023, a San Diego jury awarded $332 million to a cancer patient, finding that Monsanto didn't adequately warn of the risks of Roundup.
These large verdicts, while often reduced on appeal, signal a jury's strong conviction regarding the link between Roundup and cancer. For example, in May 2021, San Francisco U.S. District Judge Vince Chhabria denied Bayer's offer of $2 billion to settle future claims, calling it "clearly unreasonable" and highlighting the ongoing judicial scrutiny of Bayer's settlement strategies. These outcomes demonstrate a high-stakes litigation environment where Bayer faces substantial financial risks with each new trial.
To understand the specifics of these financial outcomes, you can visit our page on Roundup lawsuit settlements and payouts.
Bayer's strategy in defending against the barrage of Roundup lawsuits is multifaceted, resembling a multi-front war. The company isn't just fighting in individual trials and MDLs; it's also engaging in high-level legal arguments, aggressive lobbying, and even considering drastic corporate restructuring. The ultimate goal is to contain the financial bleeding and protect its future.
One of Bayer's primary legal arguments revolves around federal preemption, specifically under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Bayer contends that because the U.S. Environmental Protection Agency (EPA) approved Roundup's label without a cancer warning, state-level "failure-to-warn" claims should be preempted by federal law. Essentially, if the EPA says the label is fine, state courts shouldn't be able to penalize Bayer for not adding a warning.
This argument has led to a significant legal debate and even a split among federal circuit courts. While the 11th U.S. Circuit Court of Appeals rejected Bayer's preemption argument in February 2024, the 3rd U.S. Circuit Court of Appeals ruled in Monsanto and Bayer's favor in Schaffner v. Monsanto in August 2024, determining that FIFRA preempts state law. This creates a "circuit split," a disagreement between different federal appeals courts, which often signals a matter ripe for review by the U.S. Supreme Court.
We've seen this argument play out in various legal contexts, and the implications for California cases are significant. If the Supreme Court sides with Bayer on preemption, it could effectively shut down many state-level failure-to-warn claims, a core component of most Roundup lawsuits. For a deeper dive into the complexities of Monsanto's legal history, visit our page on Monsanto vs. The Public: A Guide to All Lawsuits Filed Against Monsanto.
The U.S. Supreme Court's involvement is a critical development in the latest news on the roundup settlement. On January 21, 2026, the Supreme Court announced it will hear a case involving injuries from Roundup, specifically the appeal related to John Durnell. Bayer had appealed a $1.25 billion award to Durnell, seeking the Supreme Court's review.
This is a pivotal moment for the litigation. Bayer has been pushing for the Supreme Court to take up a preemption case for some time, hoping for a ruling that would shield it from thousands of lawsuits. In July 2025, the U.S. Supreme Court asked the U.S. Solicitor General to weigh in on whether Bayer can claim preemption and sidestep Roundup lawsuits, indicating the high court's interest in this complex legal question. Bayer anticipates a Supreme Court decision on its review of a Roundup lawsuit by June 2026. A favorable ruling for Bayer on the preemption argument could effectively end thousands of current and future lawsuits, dramatically altering the landscape of the entire litigation.
Beyond the courts, Bayer is actively engaged in lobbying efforts to secure legislative protection. The company has spent considerable resources "lobbying for protection from future Roundup cancer lawsuits." This strategy involves pushing for state-level immunity bills that would shield pesticide manufacturers from lawsuits as long as their products comply with federal labeling requirements.
For example, in May 2025, North Dakota's governor signed House Bill 1318 into law, providing future litigation protections for Bayer in that state. Similarly, in March 2025, the Iowa Senate passed a bill proposed by Bayer that would shield the company from pesticide lawsuits. While these specific laws apply to other states, they illustrate a broader trend of Bayer's efforts to influence legislation, which could potentially impact the legal environment nationwide, including in California.
Bayer has even gone so far as to tell legislators that it will "stop selling Roundup in the U.S." unless lawmakers strengthen laws to protect Bayer from litigation, a statement made in March 2025. This strong stance highlights the company's determination to resolve its legal woes, potentially by removing glyphosate from its agricultural sprays sold in the U.S. This would be a significant development, signaling a strategic shift to mitigate future liabilities.
At the heart of every Roundup lawsuit is the scientific debate surrounding glyphosate, Roundup's active ingredient, and its potential link to cancer. This debate is complex, often contentious, and plays a crucial role in how juries and courts perceive the evidence. What we often see in court is a "tale of two agencies," conflicting scientific opinions, and allegations of corporate misconduct that sway public and judicial opinion.
The controversy largely stems from differing conclusions reached by prominent scientific and regulatory bodies. In 2015, the World Health Organization's International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans." This classification served as a catalyst for many of the lawsuits that followed, giving plaintiffs a credible scientific backing for their claims.
However, the U.S. Environmental Protection Agency (EPA) has taken a different stance, stating that "glyphosate is not likely to be carcinogenic to humans." This conflicting assessment creates a significant challenge in court, as both sides present expert witnesses who rely on these differing conclusions. Plaintiffs argue that the IARC's independent assessment is more reliable, while Bayer leans on the EPA's findings to defend the safety of its product. This scientific disagreement is a central legal argument in all Roundup cases, including those in California.
For a deeper understanding of the scientific arguments, refer to our page on the Roundup cancer link.
Adding another layer of complexity and controversy are the "Monsanto Papers." This collection of internal company documents, revealed during findy in early trials, has been central to plaintiffs' arguments. The papers allegedly detail Monsanto's efforts to control the narrative surrounding glyphosate's safety, including ghostwriting articles for toxicology journals, interfering with the peer-review process, attempting to influence regulators, and failing to adequately test the carcinogenicity of the combined ingredients in Roundup. These allegations paint a picture of corporate misconduct, suggesting that Monsanto actively sought to suppress information that might link its product to cancer.
In court, plaintiffs often present scientific studies alongside the "Monsanto Papers" to build their case. For example, a 2019 University of Washington study found that agricultural workers with heavy glyphosate exposure had a 41% increased risk of developing non-Hodgkin lymphoma over their lifetimes. Such studies, combined with evidence of alleged corporate cover-ups, can be highly persuasive to juries.
The primary cancer cited in Roundup lawsuits, including those in California, is non-Hodgkin lymphoma (NHL) and its various subtypes. Plaintiffs allege that exposure to glyphosate-based herbicides like Roundup caused or contributed to the development of these cancers.
Cancers Commonly Cited in Lawsuits:
For individuals who have used Roundup and subsequently received a cancer diagnosis, the latest news on the roundup settlement can be both confusing and hopeful. It's crucial to understand your potential legal options, what it takes to pursue a claim, and what kind of compensation might be available.
If you or a loved one developed cancer after using Roundup, you might qualify for a lawsuit. Generally, eligibility hinges on a few key factors:
Understanding these criteria is the first step. We strongly encourage you to consult with an experienced attorney to assess your specific situation. For a comprehensive guide to eligibility, check out our Roundup lawsuit claim complete guide.
Building a strong Roundup lawsuit requires compelling evidence to establish both your exposure to the herbicide and your subsequent cancer diagnosis. We understand that gathering this information can feel daunting, but an experienced legal team can guide you through the process.
Key Evidence Needed to Prove Your Case:
The goal is to paint a clear picture of how and when you were exposed to Roundup and how that exposure led to your health issues. Our team can help you steer the process of collecting this vital information. Learn more about what proof you need for a Roundup lawsuit.
One of the most common questions we receive is about how much a Roundup lawsuit might be worth. While it's impossible to guarantee a specific amount, we can look at past settlements and verdicts to provide some guidance.
In 2020, Bayer agreed to a massive $10.9 billion settlement to resolve about 100,000 Roundup cases. This global settlement resulted in an estimated average payout of about $150,000 per plaintiff. However, individual settlement amounts can vary widely, with lawyers estimating payouts between $5,000 and $250,000 per person.
Several factors influence the potential payout in a Roundup lawsuit:
Many settlements, especially larger batch settlements, use a tiered points system to determine individual amounts. Points are allocated based on factors like the type and duration of exposure, the plaintiff's health at the time of diagnosis, and the severity of the treatment required. This system aims to create a fair distribution based on the unique circumstances of each case.
While juries have awarded multi-billion dollar verdicts, these amounts are often reduced significantly on appeal. For instance, a $2.25 billion verdict in Pennsylvania was later slashed to $400 million. This highlights the complex nature of these cases and the importance of experienced legal representation.
For more information on what you might expect, visit our page on what is the average payout for a Roundup lawsuit?.
We understand you likely have many questions about the latest news on the roundup settlement. Here, we address some of the most common inquiries to help clarify the situation.
While there's no single "average" payout that applies to every case, we can look at past settlements for an indication. The 2020 global settlement, which involved about 100,000 cases, resulted in an estimated average payout of around $150,000 per plaintiff. However, it's crucial to understand that individual settlement amounts vary significantly. Payouts are highly case-specific, depending on factors such as the severity and type of injury, the plaintiff's age, the duration and intensity of Roundup exposure, and the extent of medical expenses and lost wages. Jury verdicts, while sometimes reaching billions of dollars, are often reduced substantially during appeals.
Not necessarily! While it might seem like the litigation has been going on forever, it is generally not too late to file a Roundup lawsuit. The key factor is your state's statute of limitations. In California, like many states, the deadline to file a personal injury lawsuit typically starts from the date of your cancer diagnosis, not your initial exposure to Roundup. This is often referred to as the "findy rule." Since non-Hodgkin lymphoma and other related cancers can take years to develop after exposure, many individuals are still within their legal window to file a claim. New cases continue to be filed, and the litigation is ongoing. We encourage you to contact an attorney as soon as possible to determine your eligibility and ensure you meet any applicable deadlines.
This is a common question, and the answer has a few nuances. In 2021, Bayer announced a significant change: it would stop selling glyphosate-based Roundup products for residential lawn and garden use in the U.S. starting in 2023. This means that if you buy Roundup today for home use, it likely contains different active ingredients. However, it's important to note that commercial and agricultural formulas of Roundup still contain glyphosate. So, while residential products have changed, glyphosate-based Roundup is still widely used in larger-scale applications. Additionally, Bayer is actively working on alternatives, having announced in July 2025 that it submitted approval applications for a new herbicide called CropKey, which would be an alternative to Roundup.
The latest news on the roundup settlement paints a clear picture: this litigation is far from over. With tens of thousands of active lawsuits, billions of dollars at stake, and a pivotal Supreme Court decision on the horizon, the legal battle will continue to evolve throughout 2026 and beyond. Bayer is fighting aggressively, but recent jury verdicts and the ongoing scientific debate continue to underscore the serious allegations against the company.
For those who have used Roundup and subsequently developed non-Hodgkin lymphoma or related cancers, understanding these developments is crucial. You still have legal options, and know your rights. Justice Hero is committed to providing comprehensive legal information and guiding you through complex legal topics. We believe in simplifying the process so you can seek justice against corporate wrongdoing.
If you believe your cancer diagnosis is linked to Roundup exposure, don't hesitate. The window for filing a claim can close, and gathering evidence takes time. Taking the first step to understand your legal standing is critical.
Learn more about your options by reviewing our Roundup Lawsuit guide.
